GLOBAL ANTIFUNGAL AGENTS MARKET FORECAST 2017-2025
KEY FINDINGS
The global antifungal agents market is projected to grow from $6400 million in 2016 to $12924 million by 2025. Due to increasing of various fungal infections awareness among people is boosting the antifungal agents market.
MARKET INSIGHTS
The antifungal agents market is segmented on the basis of drug types, therapeutic indications, applications, and geography. The antifungal agents market on the basis of drug types is segmented into echinocandins, azoles, polyenes, allylamines and others. On the basis of therapeutic indications, aspergillosis, dermatophytosis, candidiasis and others. The antifungal agents application market is segregated into topical antifungal agents and oral drugs. The antifungal agents on the basis of geography are segmented into Asia-Pacific, Europe, Rest of the World and North America.
Poor hygiene habits and the rising awareness about the antifungal agents for treatment is one of the major drivers for the antifungal agents market. The healthcare policies and programs by government and the development of drug resistance are preeminent drivers for the growth of antifungal agents market.
REGIONAL INSIGHTS
North America antifungal agents market holds the largest market share in the global antifungal agents market in 2016. The rise in the incidence of fungal infections and the developing antifungal biopharmaceuticals in the region is driving the market. Asia-Pacific is projected to be the fastest-growing region for the global antifungal agents market. Europe antifungal agents market is estimated to grow during the forecast period.
COMPETITIVE INSIGHTS
The leading market players for Antifungal agents market are Vertex Pharmaceuticals, Teva pharmaceuticals, Sanofi-Aventis, Pfizer, Novartis, Merck & co, Kramer laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, Bayer healthcare, Astellas Pharma Inc., Arbor pharmaceuticals Inc., Abbott laboratories, and 3 Baxter.
The global antifungal agents market is projected to grow from $6400 million in 2016 to $12924 million by 2025. Due to increasing of various fungal infections awareness among people is boosting the antifungal agents market.
MARKET INSIGHTS
The antifungal agents market is segmented on the basis of drug types, therapeutic indications, applications, and geography. The antifungal agents market on the basis of drug types is segmented into echinocandins, azoles, polyenes, allylamines and others. On the basis of therapeutic indications, aspergillosis, dermatophytosis, candidiasis and others. The antifungal agents application market is segregated into topical antifungal agents and oral drugs. The antifungal agents on the basis of geography are segmented into Asia-Pacific, Europe, Rest of the World and North America.
Poor hygiene habits and the rising awareness about the antifungal agents for treatment is one of the major drivers for the antifungal agents market. The healthcare policies and programs by government and the development of drug resistance are preeminent drivers for the growth of antifungal agents market.
REGIONAL INSIGHTS
North America antifungal agents market holds the largest market share in the global antifungal agents market in 2016. The rise in the incidence of fungal infections and the developing antifungal biopharmaceuticals in the region is driving the market. Asia-Pacific is projected to be the fastest-growing region for the global antifungal agents market. Europe antifungal agents market is estimated to grow during the forecast period.
COMPETITIVE INSIGHTS
The leading market players for Antifungal agents market are Vertex Pharmaceuticals, Teva pharmaceuticals, Sanofi-Aventis, Pfizer, Novartis, Merck & co, Kramer laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, Bayer healthcare, Astellas Pharma Inc., Arbor pharmaceuticals Inc., Abbott laboratories, and 3 Baxter.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUGS
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
7.1.1. UNITED STATES (U.S.) ANTIFUNGAL AGENTS MARKET
7.1.2. CANADA ANTIFUNGAL AGENTS MARKET
7.2. EUROPE ANTIFUNGAL AGENTS MARKET
7.2.1. UNITED KINGDOM (UK) ANTIFUNGAL AGENTS MARKET
7.2.2. FRANCE ANTIFUNGAL AGENTS MARKET
7.2.3. GERMANY ANTIFUNGAL AGENTS MARKET
7.2.4. SPAIN ANTIFUNGAL AGENTS MARKET
7.2.5. ITALY ANTIFUNGAL AGENTS MARKET
7.2.6. ROE ANTIFUNGAL AGENTS MARKET
7.3. ASIA PACIFIC ANTIFUNGAL AGENTS MARKET
7.3.1. INDIA ANTIFUNGAL AGENTS MARKET
7.3.2. CHINA ANTIFUNGAL AGENTS MARKET
7.3.3. JAPAN ANTIFUNGAL AGENTS MARKET
7.3.4. ROAPAC ANTIFUNGAL AGENTS MARKET
7.4. REST OF THE WORLD ANTIFUNGAL AGENTS MARKET
7.4.1. LATIN AMERICA ANTIFUNGAL AGENTS MARKET
7.4.2. MENA ANTIFUNGAL AGENTS MARKET
7.4.3. AFRICA ANTIFUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. GILEAD
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. GLAXOSMITHKLINE
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. JOHNSON & JOHNSON
9.9.1. OVERVIEW
9.9.2. PRODUCTS
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. KRAMER LABORATORIES
9.10.1. OVERVIEW
9.10.2. PRODUCTS
9.10.3. SCOT ANALYSIS
9.11. MERCK & CO.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC MOVES
9.12. NOVARTIS
9.12.1. OVERVIEW
9.12.2. PRODUCTS
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. PFIZER
9.13.1. OVERVIEW
9.13.2. PRODUCTS
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SANOFI-AVENTIS
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. VERTEX PHARMACEUTICALS
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 GLOBAL ANTIFUNGAL AGENTS MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
TABLE 2 GLOBAL ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2017-2025 ($ MILLION)
TABLE 3 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 4 GLOBAL ECHINOCANDINS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 5 DRUG USES OF TRIAZOLES
TABLE 6 GLOBAL AZOLES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 7 GLOBAL POLYENES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 8 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 9 GLOBAL ALLYLAMINES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 10 GLOBAL ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2017-2025 ($ MILLION)
TABLE 11 GLOBAL ASPERGILLOSIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 12 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 13 GLOBAL DERMATOPHYTOSIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 14 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 15 GLOBAL CANDIDIASIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 16 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 17 GLOBAL ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2017-2025 ($ MILLION)
TABLE 18 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 1 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 2 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 3 ANTIFUNGAL PASTES AND ITS EFFECT
TABLE 4 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND ITS EFFECTS
TABLE 5 GLOBAL ANTI-FUNGAL AGENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 6 NORTH AMERICA ANTI-FUNGAL MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 7 EUROPE ANTI-FUNGAL AGENT MARKET 2017-2025 ($ MILLION)
TABLE 8 FINAL CONSUMPTION OF MEDICAL GOODS AND SERVICES BY HOUSEHOLD
TABLE 9 TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2015
TABLE 10 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 11 INDIA’S HEALTHCARE SECTOR INVESTMENT
TABLE 12 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS
TABLE 13 TOTAL BURDEN OF FUNGAL INFECTIONS IN JAPAN
TABLE 14 REST OF THE WORLD ANTIFUNGAL AGENTS MARKET BY REGION 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 GLOBAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($MILLION)
FIGURE 2 HEALTHCARE PROGRAMS INITIATED BY INDIAN GOVERNMENT
FIGURE 1 ALTERNATIVE MEDICINE IN US (IN MILLION US DOLLARS)
FIGURE 2 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 GLOBAL ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 4 GLOBAL AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 5 GLOBAL POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 6 GLOBAL ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 7 GLOBAL OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 8 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
FIGURE 9 GLOBAL ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 GLOBAL DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 11 GLOBAL CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 12 GLOBAL OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 13 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 14 GLOBAL TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 15 GLOBAL TOPICAL ANTIFUNGAL AGENTS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
FIGURE 16 GLOBAL ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 17 GLOBAL ORAL DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
FIGURE 18 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 19 HEALTHCARE INVESTMENT IN THE U.S. 2012-2015 ($ BILLION)
FIGURE 20 ANTI-FUNGAL AGENTS MARKET IN THE U.S. 2017-2025 ($ MILLION)
FIGURE 21 CANADA ANTIFUNGAL AGENT MARKET 2017-2025 ($ MILLION)
FIGURE 22 PHARMACEUTICAL SALES IN DIFFERENT COUNTRIES IN EUROPE 2014 ($ MILLION)
FIGURE 23 HEALTHCARE EXPENDITURE IN UK 2010-2015 (£ BILLION)
FIGURE 24 U.K. ANTIFUNGAL AGENTS MARKET 2017-2025 ($MILLION)
FIGURE 25 INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2015 (%)
FIGURE 26 FRANCE ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 27 GERMANY ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 28 SPAIN ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 29 ITALY ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 30 ROE ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 31 PER CAPITA HEALTHCARE EXPENDITURE IN INDIA ($)
FIGURE 32 INDIA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 33 CHINA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 34 JAPAN ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 35 ROAPAC ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 36 LATIN AMERICA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 37 VARIOUS SECTORS INVESTMENTS IN THE MENA REGION
FIGURE 38 MENA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 39 AFRICA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 40 GLOBAL ANTI-FUNGAL AGENT MARKET SHARE ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUGS
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
7.1.1. UNITED STATES (U.S.) ANTIFUNGAL AGENTS MARKET
7.1.2. CANADA ANTIFUNGAL AGENTS MARKET
7.2. EUROPE ANTIFUNGAL AGENTS MARKET
7.2.1. UNITED KINGDOM (UK) ANTIFUNGAL AGENTS MARKET
7.2.2. FRANCE ANTIFUNGAL AGENTS MARKET
7.2.3. GERMANY ANTIFUNGAL AGENTS MARKET
7.2.4. SPAIN ANTIFUNGAL AGENTS MARKET
7.2.5. ITALY ANTIFUNGAL AGENTS MARKET
7.2.6. ROE ANTIFUNGAL AGENTS MARKET
7.3. ASIA PACIFIC ANTIFUNGAL AGENTS MARKET
7.3.1. INDIA ANTIFUNGAL AGENTS MARKET
7.3.2. CHINA ANTIFUNGAL AGENTS MARKET
7.3.3. JAPAN ANTIFUNGAL AGENTS MARKET
7.3.4. ROAPAC ANTIFUNGAL AGENTS MARKET
7.4. REST OF THE WORLD ANTIFUNGAL AGENTS MARKET
7.4.1. LATIN AMERICA ANTIFUNGAL AGENTS MARKET
7.4.2. MENA ANTIFUNGAL AGENTS MARKET
7.4.3. AFRICA ANTIFUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. GILEAD
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. GLAXOSMITHKLINE
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. JOHNSON & JOHNSON
9.9.1. OVERVIEW
9.9.2. PRODUCTS
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. KRAMER LABORATORIES
9.10.1. OVERVIEW
9.10.2. PRODUCTS
9.10.3. SCOT ANALYSIS
9.11. MERCK & CO.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC MOVES
9.12. NOVARTIS
9.12.1. OVERVIEW
9.12.2. PRODUCTS
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. PFIZER
9.13.1. OVERVIEW
9.13.2. PRODUCTS
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SANOFI-AVENTIS
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. VERTEX PHARMACEUTICALS
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 GLOBAL ANTIFUNGAL AGENTS MARKET BY GEOGRAPHY 2017-2025 ($MILLION)
TABLE 2 GLOBAL ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2017-2025 ($ MILLION)
TABLE 3 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 4 GLOBAL ECHINOCANDINS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 5 DRUG USES OF TRIAZOLES
TABLE 6 GLOBAL AZOLES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 7 GLOBAL POLYENES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 8 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 9 GLOBAL ALLYLAMINES MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 10 GLOBAL ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2017-2025 ($ MILLION)
TABLE 11 GLOBAL ASPERGILLOSIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 12 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 13 GLOBAL DERMATOPHYTOSIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 14 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 15 GLOBAL CANDIDIASIS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 16 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 17 GLOBAL ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2017-2025 ($ MILLION)
TABLE 18 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 1 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 2 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 3 ANTIFUNGAL PASTES AND ITS EFFECT
TABLE 4 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND ITS EFFECTS
TABLE 5 GLOBAL ANTI-FUNGAL AGENT MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 6 NORTH AMERICA ANTI-FUNGAL MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 7 EUROPE ANTI-FUNGAL AGENT MARKET 2017-2025 ($ MILLION)
TABLE 8 FINAL CONSUMPTION OF MEDICAL GOODS AND SERVICES BY HOUSEHOLD
TABLE 9 TOTAL BURDEN OF FUNGAL INFECTIONS IN SPAIN 2015
TABLE 10 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 11 INDIA’S HEALTHCARE SECTOR INVESTMENT
TABLE 12 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS
TABLE 13 TOTAL BURDEN OF FUNGAL INFECTIONS IN JAPAN
TABLE 14 REST OF THE WORLD ANTIFUNGAL AGENTS MARKET BY REGION 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 GLOBAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($MILLION)
FIGURE 2 HEALTHCARE PROGRAMS INITIATED BY INDIAN GOVERNMENT
FIGURE 1 ALTERNATIVE MEDICINE IN US (IN MILLION US DOLLARS)
FIGURE 2 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 GLOBAL ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 4 GLOBAL AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 5 GLOBAL POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 6 GLOBAL ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 7 GLOBAL OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 8 GLOBAL OTHERS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
FIGURE 9 GLOBAL ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 GLOBAL DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 11 GLOBAL CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 12 GLOBAL OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 13 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 14 GLOBAL TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 15 GLOBAL TOPICAL ANTIFUNGAL AGENTS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
FIGURE 16 GLOBAL ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 17 GLOBAL ORAL DRUGS MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
FIGURE 18 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 19 HEALTHCARE INVESTMENT IN THE U.S. 2012-2015 ($ BILLION)
FIGURE 20 ANTI-FUNGAL AGENTS MARKET IN THE U.S. 2017-2025 ($ MILLION)
FIGURE 21 CANADA ANTIFUNGAL AGENT MARKET 2017-2025 ($ MILLION)
FIGURE 22 PHARMACEUTICAL SALES IN DIFFERENT COUNTRIES IN EUROPE 2014 ($ MILLION)
FIGURE 23 HEALTHCARE EXPENDITURE IN UK 2010-2015 (£ BILLION)
FIGURE 24 U.K. ANTIFUNGAL AGENTS MARKET 2017-2025 ($MILLION)
FIGURE 25 INVESTMENT MADE BY DIFFERENT AGENTS IN FRANCE 2015 (%)
FIGURE 26 FRANCE ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 27 GERMANY ANTI-FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 28 SPAIN ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 29 ITALY ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 30 ROE ANTI-FUNGAL MARKET 2017-2025 ($ MILLION)
FIGURE 31 PER CAPITA HEALTHCARE EXPENDITURE IN INDIA ($)
FIGURE 32 INDIA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 33 CHINA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 34 JAPAN ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 35 ROAPAC ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 36 LATIN AMERICA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 37 VARIOUS SECTORS INVESTMENTS IN THE MENA REGION
FIGURE 38 MENA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 39 AFRICA ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 40 GLOBAL ANTI-FUNGAL AGENT MARKET SHARE ANALYSIS
